Changes in bone mineral density and serum calcium levels after romosozumab treatmet in postmenopausal osteoporosis patients:About short-term results at 6 months

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1040190111

Enrollment

Registered

2020-01-31

Start date

2020-01-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary osteoprosis osteoprosis

Interventions

None

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1.postmenopausal women with osteoporosis 2.patients who used romosozumab for 6 months

Exclusion criteria

Exclusion criteria: 1.patients who are allergic to romosozumab 2.hypocacemia

Design outcomes

Primary

Measure	Time frame
Bone denisity change	—

Secondary

Measure	Time frame
1.Bone turneover makers at 6 months 2.Adverse events at 6 months 3.New fracture at 6 months	—

Contacts

Public ContactTOMONORI KOBAYAKAWA

Orthopedic and Rheumatologic clinic

kobatomo0109@yahoo.co.jp+81-538-43-5800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026